From $2B to $13.6B: How Greg Lucier Builds Medtech Companies for Acquisition
Key Takeaways
- Category ownership matters more than product superiority when it comes to acquisition premium
- Operational clarity (consequential leadership where decisions have real consequences) is what makes a company acquirable vs. just financially interesting
- Building with a strategic acquirer in mind means solving their commercial problem, not just building a good product
- The PE-to-strategic pathway is increasingly the dominant medtech exit architecture
- Thought leadership before it was conventional is a pattern in every major value-creation arc Lucier has been part of
Most medtech founders build companies they hope to sell. Greg Lucier builds companies that strategists need to buy.
Over his career he has taken invitrogen from a ~$2B genomics tools company to Life Technologies, sold to Thermo Fisher for $13.6B. He led NuVasive through a critical growth phase. And now he's building Corza Medical (a PE-backed surgical portfolio company challenging J&J, Medtronic, and Baxter by acquiring adjacent assets under a single brand).
The operating philosophy has stayed the same throughout: utter clarity of execution, category ownership from day one, thought leadership before it was a recognized strategy.
I sat down with Greg on The State of MedTech to understand how he thinks about building medtech for acquisition. Lucier treats it as a company-building philosophy.
Watch the full episode on YouTube
The GE Foundation: Why Clarity of Execution Matters
Greg Lucier's career started at GE Medical. Before invitrogen. Before the $13.6B exit. Before Corza.
GE Medical was (at the time he joined) part of what many considered the world's most valuable company. And what he learned there shaped everything that followed:
"It was a very Darwinian culture. Survival of the fittest. If you made decisions, you bore the consequences, good or bad, and it created utter clarity to execution. That's why the company did so darn well. And I think those lessons have to carry forth. You look at all the great companies they have that utter clarity of what they're trying to get done each and every day."
— Greg Lucier, CEO, Corza Medical — The State of MedTech, Ep. 267
Consequential leadership. When decisions have real consequences (not managed consequences, not softened feedback, but actual accountability) it creates operational clarity that compounds over years.
This is the opposite of how most medtech companies operate. Decisions get diffused across committees. Accountability is distributed until nobody owns the outcome. Six months later, the company hasn't moved.
Acquirers feel the difference in the first day of diligence. A company where decisions have consequences has consistent processes, predictable output, and clear ownership of commercial results. A company where decisions are socialized has variance, exceptions, and founder-dependency in every deal.
Lucier built both invitrogen and Corza with the GE model: consequential leadership at every level, utter clarity on what gets done each day, no ambiguity about who owns what.
Betting on Yourself: The Invitrogen Decision
By the time Greg Lucier joined invitrogen, he was at GE Medical (one of the most coveted positions in corporate America). Leaving made no obvious sense.
He left anyway.
"At some point in your life, you've got to make a bet on yourself. And for me, that was that moment in time."
— Greg Lucier — The State of MedTech, Ep. 267
The bet paid off at $13.6B.
But the specific form of the bet matters. He didn't leave GE Medical to join a startup and hope for the best. He joined invitrogen with a clear thesis: genomics research tools were a category that would define biology for decades. The company with the best tools would own the category. Category ownership would translate directly to acquisition premium.
Thermo Fisher didn't pay $13.6B for a good product portfolio. They paid $13.6B to own the category (to become the default infrastructure for genomics research globally). Lucier built toward that outcome from day one.
Building Corza: The Challenger Architecture
Lucier's current project, Corza Medical, is a different model (PE-backed from the start, acquisition-driven rather than organic growth).
The thesis: the major surgical device companies have near-monopolistic positions in several specialty surgical categories. Corza builds and acquires complementary assets under a single brand to compete across multiple adjacent categories simultaneously.
The formation: GTCR private equity backed Lucier to merge Surgical Specialties with TachoSil manufacturing (acquired from Takeda) and then Katena. The Corza brand is the jersey every acquired company puts on when it joins:
"We've bought a number of companies and we tell them: bring your values with you. We'll mold our combined values and go forward together in a new form. You've got to take off the old jersey to go to a new place."
— Greg Lucier — The State of MedTech, Ep. 267
This is the PE-to-strategic architecture in practice. Lucier is assembling a portfolio that a major surgical strategic will have to engage with (not because Corza beats them on a product-by-product basis, but because Corza will own enough adjacent categories that ignoring them becomes a competitive liability).
What Makes a Medtech Company Worth Buying
Three things show up consistently across what Lucier builds:
1 ) The category position is clear and defensible.
Life Technologies owned genomics research infrastructure. An acquirer couldn't build around them (they had to go through them). Corza is building toward the same position in specialty surgical categories.
2 ) The operational model runs without the founder.
Lucier builds with consequential leadership at every level because a company that requires the founder in every deal is a company an acquirer can't underwrite. Revenue has to be predictable beyond the founder's relationships.
3 ) Thought leadership was built before it was conventional.
The companies that exit for the highest multiples are the ones that spent years building market credibility, not just balance sheet metrics.
Applying This to Your Company
If you're building a medtech company and thinking about exit, the Lucier framework comes down to three questions.
What category are you creating or dominating? Not what product are you building, but what market position will be defensible and distinct? If your answer is "we're in the SNM market" rather than "we're building the rechargeable SNM category for active patients," you're building for commodity pricing.
Does your company run on process or personality? If you're in every major deal, every clinical conversation, every budget approval, you're building a service business. Acquirers don't pay 8-10x revenue for founder-dependent revenue. Build the operational model that runs without you.
Who is your strategic acquirer in five years, and what problem will they have? The earlier you can answer that specifically, the earlier you can start solving it. Lucier built invitrogen to solve Thermo Fisher's genomics infrastructure gap years before Thermo Fisher knew they needed to solve it. That's thesis-driven company building.
For the broader exit playbook across six founders and $20B in outcomes, see how to exit a medtech company. For the commercial foundation that drives exit value, see medtech commercialization strategy.
Frequently Asked Questions
How do you build a medtech company for acquisition?
The founders who've done it repeatedly share three traits: they build category-dominant companies rather than just good ones, maintain operational consistency over years, and develop acquirer relationships long before any formal process. The product has to work. But category ownership and operational clarity determine the multiple.
What is Corza Medical?
Corza Medical is a surgical portfolio company backed by GTCR private equity, led by Greg Lucier. Formed through the merger of Surgical Specialties with TachoSil manufacturing (acquired from Takeda) and then Katena. The thesis: build a portfolio across adjacent surgical specialties to compete with the major surgical device companies at scale.
What did Greg Lucier do before Corza Medical?
Lucier started at GE Medical, then joined invitrogen, which he built into Life Technologies (acquired by Thermo Fisher for $13.6B in 2013). He subsequently held leadership roles at NuVasive before founding Corza Medical with GTCR private equity backing.
PE vs. strategic exit: what's different?
Strategic acquirers pay for market position, IP, and commercial fit (they need what you've built to solve a competitive problem). PE acquirers pay for operational improvement potential and portfolio synergies. Lucier operates with PE backing but builds toward strategic acquirer interest. His Corza thesis only pays off at scale if a strategic eventually has to engage with the portfolio.
Listen to Greg Lucier's Full Story
Greg Lucier's full conversation on The State of MedTech covers his career arc from GE Medical through Life Technologies, NuVasive, and the Corza Medical build. Watch on YouTube. Subscribe wherever you listen to podcasts.
About Greg Lucier
Greg Lucier is the CEO of Corza Medical, a GTCR-backed surgical portfolio company. He previously served as CEO of Life Technologies, growing it from approximately $2 billion to a $13.6 billion acquisition by Thermo Fisher Scientific in 2013. He began his career at GE Medical Systems.
About the Author
Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.